UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop

BMC health services research, 2021-05, Vol.21 (1), p.412-412, Article 412

2021

Link zum Volltext

Verfügbarkeit prüfen

Indication-specific pricing of pharmaceuticals in the US healthcare system

Journal of comparative effectiveness research, 2017-07, Vol.6 (5), p.397-404

2017

Link zum Volltext

Verfügbarkeit prüfen

HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION

International journal of technology assessment in health care, 2013-10, Vol.29 (4), p.353-359

2013

Link zum Volltext

Verfügbarkeit prüfen

Public participation in decision-making on the coverage of new antivirals for hepatitis C

Journal of health organization and management, 2016-08, Vol.30 (5), p.769-785

2016

Link zum Volltext

Verfügbarkeit prüfen

How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice

Health research policy and systems, 2015-01, Vol.13 (1), p.1-1, Article 1

2015

Link zum Volltext

Verfügbarkeit prüfen

DESCRIBE DECISION-MAKING SYSTEMS, ASSESS HEALTH TECHNOLOGY ASSESSMENT REPORTS

International journal of technology assessment in health care, 2012-04, Vol.28 (2), p.168-168

Henshall, Chris

2012

Link zum Volltext

Verfügbarkeit prüfen

Not cost-effective at zero price: valuing and paying for combination therapies in cancer

Expert review of pharmacoeconomics & outcomes research, 2021-05, Vol.21 (3), p.331-333

2021

Link zum Volltext

Verfügbarkeit prüfen

USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT”

International journal of technology assessment in health care, 2012-07, Vol.28 (3), p.203-210

2012

Link zum Volltext

Verfügbarkeit prüfen

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?

International journal of technology assessment in health care, 2016-01, Vol.32 (4), p.191-199

2016

Link zum Volltext

Verfügbarkeit prüfen

Gene therapy: evidence, value and affordability in the US health care system

Journal of comparative effectiveness research, 2018-01, Vol.7 (1), p.15-28

2018

Link zum Volltext

Verfügbarkeit prüfen

Real-world evidence for coverage decisions: opportunities and challenges

Journal of comparative effectiveness research, 2018-12, Vol.7 (12), p.1133-1143

2018

Link zum Volltext

Verfügbarkeit prüfen

ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA

International journal of technology assessment in health care, 2017-01, Vol.33 (2), p.315-322

2017

Link zum Volltext

Verfügbarkeit prüfen

ADAPTIVE APPROACHES TO LICENSING, HEALTH TECHNOLOGY ASSESSMENT, AND INTRODUCTION OF DRUGS AND DEVICES

International journal of technology assessment in health care, 2014-07, Vol.30 (3), p.241-249

2014

Link zum Volltext

Verfügbarkeit prüfen

IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT

International journal of technology assessment in health care, 2015-01, Vol.31 (4), p.201-206

2015

Link zum Volltext

Verfügbarkeit prüfen

TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES

International journal of technology assessment in health care, 2016-01, Vol.32 (3), p.160-166

2016

Link zum Volltext

Verfügbarkeit prüfen

The impact of Payback research: developing and using evidence in policy

Research evaluation, 2011-09, Vol.20 (3), p.257-258

Henshall, Chris

2011

Link zum Volltext

Verfügbarkeit prüfen

OP03 Optimizing The Use Of RWE In HTA: Lessons From The ICER Summit

International journal of technology assessment in health care, 2018, Vol.34 (S1), p.1-2

2018

Link zum Volltext

Verfügbarkeit prüfen

TOWARD A SHIFTING HEALTH TECHNOLOGY ASSESSMENT PARADIGM: REACTIONS TO POLICY FORUM DISCUSSIONS

International journal of technology assessment in health care, 2015-01, Vol.31 (4), p.228-229

2015

Link zum Volltext

Verfügbarkeit prüfen

TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS

International journal of technology assessment in health care, 2016-01, Vol.32 (3), p.167-174

2016

Link zum Volltext

Verfügbarkeit prüfen

VP87 Extrapolation From Progression Free Survival To Overall Survival In Oncology

International journal of technology assessment in health care, 2017, Vol.33 (S1), p.188-189

2017

Link zum Volltext

Verfügbarkeit prüfen

Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals

Journal of comparative effectiveness research, 2021-05, Vol.10 (7), p.537-547

2021

Link zum Volltext

Verfügbarkeit prüfen

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?-ERRATUM

International journal of technology assessment in health care, 2016-01, Vol.32 (6), p.407-407

2016

Link zum Volltext

Verfügbarkeit prüfen

Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit

Journal of comparative effectiveness research, 2019-10, Vol.8 (13), p.1045-1054

2019

Link zum Volltext

Verfügbarkeit prüfen

A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions

Journal of comparative effectiveness research, 2018-12, Vol.7 (12), p.1145-1152

2018

Link zum Volltext

Verfügbarkeit prüfen

Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities

International journal of technology assessment in health care, 2011-07, Vol.27 (3), p.253-260

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieEconomic Geography

Zeitschrift / SerieEuropean Journal Of Epidemiology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(52)
Tagungsberichte
(2)

Sprache

Englisch
(54)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(33)
Health Care Sciences & Services
(27)
Humans
(20)
Health Technology Assessment
(17)
Medical Informatics
(17)
Decision Making
(16)
Public, Environmental & Occupational Health
(16)
Patients
(13)
Reimbursement
(12)
Technology Assessment
(10)
Health Care
(9)
Regulatory Approval
(9)
Policy Making
(8)
Technology
(8)
Drugs
(7)
Health
(7)
Policies
(7)
Collaboration
(6)
Health Policy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop

Indication-specific pricing of pharmaceuticals in the US healthcare system

HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION

Public participation in decision-making on the coverage of new antivirals for hepatitis C

How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice

DESCRIBE DECISION-MAKING SYSTEMS, ASSESS HEALTH TECHNOLOGY ASSESSMENT REPORTS

Not cost-effective at zero price: valuing and paying for combination therapies in cancer

USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT”

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?

Gene therapy: evidence, value and affordability in the US health care system

Real-world evidence for coverage decisions: opportunities and challenges

ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA

ADAPTIVE APPROACHES TO LICENSING, HEALTH TECHNOLOGY ASSESSMENT, AND INTRODUCTION OF DRUGS AND DEVICES

IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT

TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES

The impact of Payback research: developing and using evidence in policy

OP03 Optimizing The Use Of RWE In HTA: Lessons From The ICER Summit

TOWARD A SHIFTING HEALTH TECHNOLOGY ASSESSMENT PARADIGM: REACTIONS TO POLICY FORUM DISCUSSIONS

TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS

VP87 Extrapolation From Progression Free Survival To Overall Survival In Oncology

Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals

CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?-ERRATUM

Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit

A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions

Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities

Aktive Filter

Suchergebnisse filtern